Mode
Text Size
Log in / Sign up
N/A Completed N=25 Randomized Other

Evaluation of Physician-based Decision Support

Type 1 diabetes mellitus · MDI · CGM · Exercise
Source: ClinicalTrials.gov NCT03443713 ↗
Enrolled (actual)
25
Serious AEs
0.0%
Results posted
Mar 2020
Primary outcomePrimary: Percent of Time With Sensed Glucose 70-180 mg/dl — 58.8; 51.2; 59.3 percentage of time

Summary

The goal of this study is to assess the impact of physician-driven insulin setting changes in type 1 patients using multiple daily injection insulin therapy with exercise. This is a short outpatient study with multiple outpatient and home exercise sessions with an assigned type of exercise.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent of Time With Sensed Glucose 70-180 mg/dl
53.6; 51.0; 50.4 —
PRIMARY
Percent of Time With Sensed Glucose Less Than 70 mg/dl
3.8; 2.2; 3.1 —
SECONDARY
Percent of Time With Sensed Glucose Less Than 54 mg/dl
0.7; 0.5; 0.8 —
SECONDARY
Mean Sensed Glucose
174.0; 184.1; 183.0 —

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of type 1 diabetes mellitus for at least 1 year.
  • Male or female subjects 18 to 50 years of age.
  • Physically willing and able to perform 30 min of exercise (as determined by the investigator after reviewing the subject's activity level).
  • Use of multiple daily insulin injections (MDI).
  • A1C ≥7.0% at the time of screening.
  • Current use of a smart phone.
  • Willingness to follow all study procedures, including attending all clinic visits.
  • Willingness to sign informed consent and HIPAA documents.

Exclusion Criteria

  • Female of childbearing potential who is pregnant or intending to become pregnant or breast-feeding, or is not using adequate contraceptive methods. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence.
  • Any cardiovascular disease, defined as a clinically significant EKG abnormality at the time of screening or any history of: stroke, heart failure, myocardial infarction, angina pectoris, or coronary arterial bypass graft or angioplasty. Diagnosis of 2nd or 3rd degree heart block or any non-physiological arrhythmia judged by the investigator to be exclusionary.
  • Renal insufficiency (GFR < 60 ml/min, using the MDRD equation as reported by the OHSU laboratory).
  • Liver failure, cirrhosis, or any other liver disease that compromises liver function as determined by the investigator.
  • Hematocrit of less than 36% for men, less than 32% for women.
  • History of severe hypoglycemia during the past 12 months prior to screening visit or hypoglycemia unawareness as judged by the investigator. Subjects will complete a hypoglycemia awareness questionnaire. Subjects will be excluded for four or more R responses.
  • Adrenal insufficiency.
  • Any active infection.
  • Known or suspected abuse of alcohol, narcotics, or illicit drugs.
  • Seizure disorder.
  • Active foot ulceration.
  • Peripheral arterial disease.
  • Major surgical operation within 30 days prior to screening.
  • Use of an investigational drug within 30 days prior to screening.
  • Chronic usage of any immunosuppressive medication (such as cyclosporine, azathioprine, sirolimus, or tacrolimus).
  • Bleeding disorder or platelet count below 50,000.
  • Allergy to aspart or glargine insulin.
  • Need for uninterrupted treatment of acetaminophen.
  • Current administration of oral or parenteral corticosteroids.
  • Any life threatening disease, including malignant neoplasms and medical history of malignant neoplasms within the past 5 years prior to screening (except basal and squamous cell skin cancer).
  • Beta blockers or non-dihydropyridine calcium channel blockers.
  • Current use of any medication intended to lower glucose other than insulin (ex. use of liraglutide).
  • A positive response to any of the questions from the Physical Activity Readiness Questionnaire with one exception: subject will not be excluded if he/she takes a single blood pressure medication that doesn't impact heart rate and blood pressure is controlled on the medication (blood pressure is less than 140/90 mmHg).
  • Any chest discomfort with physical activity, including pain or pressure, or other types of discomfort.
  • Any clinically significant disease or disorder which in the opinion of the Investigator may jeopardize the subject's safety or compliance with the protocol.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03443713). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search